Study of Regn4336 administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer
Enrolling By Invitation
18 years - 99 years
Male
Phase
N/A
199 participants needed
1 Location
Brief description of study
This research study is designed to learn more about the safety and effectiveness of REGN4336 alone or in combination with cemiplimab given to individuals who have been diagnosed with Prostate Cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Prostate Cancer
-
Age: 18 years - 99 years
-
Gender: Male
Males, Over 18 years of age, Histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma
Updated on
04 Aug 2024.
Study ID: 849802
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
